2025年美国生命科学行业报告

United States Life Sciences 2025: Resilience and Transformation

• Introduction: The US life sciences sector navigates uncertainty amid rebound from a biotech bear market, driven by innovation hubs but facing patent cliffs, geopolitical risks, and evolving regulations. The industry emphasizes resilience and efficiency.

• Financial Environment: Venture capital shifted toward later-stage assets, with M&A activity surging due to patent expirations projected to lose US$300 billion by 2028. Challenges include reduced NIH funding and cautious investor sentiment, but opportunities arise from GLP-1 drug demand and CDMO capacity expansion.

• Regulation and Geopolitics: Regulatory unpredictability persists, influenced by the BIOSECURE Act, which may restrict Chinese CDMOs. Tariffs could raise manufacturing costs, prompting supply chain diversification. The FDA faces scrutiny, with a push for more digital tools to expedite reviews.

• Drug Discovery and Development: AI and machine learning are accelerating drug discovery by optimizing trials and reducing costs, especially in oncology and immuno-oncology. GLP-1 receptor agonists dominate the market, while biologics, peptides, and cell and gene therapies (CGT) lead innovation, with approvals tripling in key areas.

• Contract Manufacturing: CDMOs are expanding biologics and advanced therapy capabilities to meet demand, particularly for GLP-1 drugs. US manufacturers are investing domestically to counter China reliance, fostering partnerships with pharma and startups.

• Regional Hubs: California, Massachusetts, and Texas are key innovation clusters, with biotech hubs driving collaboration. States like New Jersey and Ohio focus on cell and gene therapies, benefiting from academic research and government incentives.

• Emerging Technologies: Digital health and AI are transforming drug development, with generative AI showing high potential for efficiency gains. Supply chain innovations, including cold chain logistics and digital platforms, enhance patient-centricity.

• Challenges and Opportunities: Cybersecurity, regulatory compliance, and talent shortages remain barriers. Opportunities lie in personalized medicine, sustainable manufacturing, and global partnerships, with the industry aiming for transformative change through digital integration.

• Conclusion: The sector is poised for growth, supported by robust ecosystems and technological advancements, despite ongoing challenges. M&A and innovation will shape the path forward, reinforcing the US as a leader in life sciences.